Ivabradine in acute care: Revisiting the funny current in critical care context Authors: Arun Mukesh, Ankur Sharma, Nikhil Kothari Published: 2025 ABSTRACT AbstractIvabradine, a selective inhibitor of the funny current in the sinoatrial node, has emerged as a promising agent for heart rate modulation in acute and critical care settings. Unlike beta-blockers, ivabradine reduces heart rate without affecting myocardial contractility, making it a valuable option for patients contraindicated for traditional therapies. This review examines its mechanism of action, clinical applications, comparative efficacy, and safety profile. It incorporates recent literature to assess its expanding role in managing acute coronary syndrome, acute decompensated heart failure, and sepsis-induced tachycardia.Keywords: Ivabradine, Heart rate control, Tachycardia, Heart failure, Beta blocker, Acute care Core Tip: Ivabradine reduces heart rate by specifically inhibiting the funny current in the sinoatrial node, without impacting myocardial contractility or blood pressure. This distinctive characteristic renders it an appealing choice for critically sick patients for whom beta-blockers are contraindicated or poorly tolerated. Recent studies corroborate its significance in acute scenarios, including acute decompensated heart failure, acute coronary syndrome, and sepsis-induced tachycardia, where a higher heart rate exacerbates outcomes. This review looks at the mechanism of action, clinical uses, comparative effectiveness, and safety profile. INTRODUCTION Heart rate control is a critical determinant in managing acute cardiovascular conditions. Traditional agents like beta blockers achieve this but may cause hypotension and bradycardia, limiting their use in acute care, especially in patients with decompensated heart failure[1,2]. Ivabradine selectively inhibits the funny current, reducing heart rate without affecting myocardial contractility. Initially approved for the treatment of chronic heart failure, recent studies have investigated its efficacy in acute care settings (Figure 1). This review compiles recent studies to evaluate the growing significance of ivabradine in critical care settings. Ivabradine in acute care. LV: Left ventricle; PCI: Percutaneous coronary intervention; ADHF: Acute decompensated heart failure; HR: Heart rate; MODS: Multi-organ dysfunction syndrome; RCT: Randomised controlled trial; ICU: Intensive care unit. MECHANISM OF ACTION The funny current (If) is a mixed sodium-potassium inward current contributing to spontaneous depolarisation in sinoatrial node cells. Ivabradine blocks the channel responsible for the cardiac pacemaker current, which regulates heart rate. This results in prolonged diastolic time and reduced heart rate[3]. Ivabradine selectively inhibits the If current, reducing heart rate without adverse inotropic effects. This unique mechanism offers advantages in acute cardiovascular conditions, where tachycardia worsens myocardial oxygen consumption and leads to hemodynamic instability (Figure 2 and Table 1)[4-12]. Mechanism of action of ivabradine. HR: Heart rate. Table 1Use of ivabradine in intensive care unit Ref. Study population Study type No. of patients Outcome measured Implications for clinical practice Zheng et al[4], 2024SepsisProspective, multicenter, randomised, open-label (n = 172)Difference in reduction in HR below 95 bpm and the effect of ivabradine on hemodynamics between the standard treatment group and the ivabradine group within the first 96 hours after randomisation Trial ongoingColombo et al[5], 2022Cardiogenic shock on mechanical circulatory support Case series (n = 6)HR, stroke volume, ECMO flow, vasopressor requirementsSignificant reduction in HR observed after ivabradine administration. SV improvement allowing the reduction of ECMO flow support and vasopressors administrationDatta et al[6], 2021Septic shockRCT (n = 60)HR, stroke volume, vasopressor dose, survival outcomesEnteral ivabradine is effective in reducing HR, improving haemodynamic parameters, and cardiac functionNguyen et al[7], 2018Low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgeryMulticenter RCT (n = 19) HR, cardiac index, continuous CO monitoringIV ivabradine achieved effective and rapid correction of sinus tachycardia. Simultaneously, stroke volume and systolic blood pressure increased, suggesting a beneficial effect of this treatment on tissue perfusionNuding et al[8], 2018Multiple organ dysfunction syndrome Single-centre RCT (n = 70) HR reduction ≥ 10 bpm at 96 hours, hemodynamics, disease severity, vasopressor use, mortalityHR reduction after oral ivabradine did not differ significantly between groups. It did not affect hemodynamics or disease severityBarillà et al[9], 2016STelevation myocardial infarction complicated by cardiogenic shockSingle-centre RCT (n = 58)HR reduction, clinical, and hemodynamic outcomesAssociated with a short-term favourable outcome and can be effectively administered by nasogastric intubationGallet et al[10], 2014Severe systolic dysfunctionRCT (n = 22) HR, diastolic function, perfusion, cardiac outputDemonstrates the safety and potential benefit of as HR HR-lowering agent De Santis et al[11], 2014MODSCase report (n = 3)Hemodynamic variablesHR reduction in MODS patientsFranke et al[12], 2011Acute heart failure due to myocarditisCase report (n = 2)Hemodynamic variablesBeneficially influence outcome by allowing optimisation of the patient′s HRSwedberg et al[1], 2010Chronic heart failure Randomised placebo-controlled (n = 6558)Composite of cardiovascular death or hospital admission for worsening heart failureHR is reduced with improvement in clinical outcomesHR: Heart rate; ECMO: Extracorporeal membrane oxygenation; SV: Stroke volume; MODS: Multi-organ dysfunction syndrome; RCT: Randomised controlled trial. Use of ivabradine in intensive care unit HR: Heart rate; ECMO: Extracorporeal membrane oxygenation; SV: Stroke volume; MODS: Multi-organ dysfunction syndrome; RCT: Randomised controlled trial. ACUTE CORONARY SYNDROME An elevated heart rate in acute coronary syndrome (ACS) increases myocardial oxygen demand, thereby exacerbating ischemia. Ivabradine's ability to selectively lower heart rate has been evaluated in several trials. Calabrò et al[13] indicated its effectiveness in reducing heart rate and improving left ventricular function, particularly in patients undergoing primary percutaneous coronary intervention. They suggested that ivabradine also aids in left ventricular remodeling post-ST-segment elevation myocardial infarction. ACUTE DECOMPENSATED HEART FAILURE Sinus tachycardia worsens symptoms and prognosis in patients with acute decompensated heart failure. Beta-blockers are effective but poorly tolerated in patients with hypotension. Ivabradine provides an alternative by selectively controlling heart rate without affecting contractility. A clinical trial reported that ivabradine improved heart rate control and reduced hospital stay duration in acute decompensated heart failure patients who were refractory to beta-blockers[14]. SEPSIS AND MULTIPLE ORGAN DYSFUNCTION SYNDROME Sepsis-induced tachycardia contributes to hemodynamic instability and worsens outcomes. Ivabradine’s selective heart rate reduction has been explored in septic patients. A prospective trial demonstrated improved hemodynamic parameters, including cardiac output and tissue perfusion, without increasing adverse effects[4]. COMPARATIVE EFFICACY: IVABRADINE VS BETA-BLOCKERS A prospective study compared ivabradine to beta-blockers in patients with ACS, observing both to be equally effective in reducing heart rate. However, ivabradine was better tolerated in patients with contraindications to beta blockers[15]. Unlike beta-blockers, ivabradine does not affect blood pressure or contractility, making it suitable for specific patient populations. SAFETY PROFILE Ivabradine has a favourable safety profile, characterised by mild, reversible side effects. The most common adverse effects include bradycardia (often dose-dependent) and visual disturbances (transient effects due to retinal If channel inhibition). Importantly, ivabradine lacks the negative inotropic and vasodilatory properties of beta-blockers, making it a safer alternative in patients with hypotension or left ventricular dysfunction (Table 2)[16]. Table 2Comparison of ivabradine and beta-blockers Variable Ivabradine Beta-blockers MechanismBlocks If channels in SA node (reduces HR only)Block β1/β2-adrenergic receptors (reduces HR + BP)Common side effectsLuminous phenomena (visual brightness). Bradycardia. Headache. Rare: Atrial fibrillationFatigue. Cold. hands/feet. Bronchospasm (worsens COPD/asthma) Erectile dysfunction. Sleep disturbances. DepressionMetabolic effectsNeutral (no impact on glucose/Lipids)May worsen: Insulin resistance. Triglycerides (↑). HDL (↓)ContraindicationsHR < 60 bpm. Acute heart failure. Pacemaker-dependentAsthma/COPD. Severe bradycardia. Heart block (2nd/3rd degree)AdvantagesPure HR control. Safe in lung diseases. No sexual dysfunction. No metabolic interferenceBroader benefits (angina, HTN, post-MI). Lower costUsesCOPD/asthma patients. Diabetes patients. HR reduction without BP effectsHypertension. Post-heart attack. ArrhythmiasHR: Heart rate; BP: Blood pressure; HDL: High-Density Lipoprotein; COPD: Chronic obstructive pulmonary disease; HTN: Hypertension, MI: Myocardial infarction; SA: Sinoatrial; If: Funny current. Comparison of ivabradine and beta-blockers HR: Heart rate; BP: Blood pressure; HDL: High-Density Lipoprotein; COPD: Chronic obstructive pulmonary disease; HTN: Hypertension, MI: Myocardial infarction; SA: Sinoatrial; If: Funny current. LIMITATIONS AND FUTURE DIRECTIONS Despite encouraging findings supporting ivabradine's role in acute care, several challenges persist, including the reliance on small sample sizes in clinical trials, which may limit the generalizability of results, the relatively short follow-up durations that restrict assessments of long-term effectiveness and safety, and the lack of comprehensive long-term efficacy data in critically ill patients. Future large-scale, multicenter, randomized controlled trials are needed to determine the definitive role of ivabradine in acute and critical care settings. CONCLUSION Ivabradine represents a novel approach to heart rate modulation in the acute care setting. Its selective inhibition of the If provides a heart rate reduction strategy without compromising myocardial contractility, differentiating it from beta-blockers. While current evidence suggests potential benefits in heart rate control without adverse hemodynamic effects, robust data from diverse patient populations are lacking. Future large-scale studies should aim to assess long-term outcomes, optimal dosing strategies, and potential interactions with other critical care medications to support the broader use of ivabradine in intensive care settings. Footnotes Conflict-of-interest statement: The authors declare no conflict of interest. Provenance and peer review: Invited article; Externally peer reviewed. Peer-review model: Single blind Specialty type: Critical care medicine Country of origin: India Peer-review report’s classification Scientific Quality: Grade B Novelty: Grade C Creativity or Innovation: Grade C Scientific Significance: Grade B P-Reviewer: Zhang RX, FACC, MD, Associate Professor, China S-Editor: Liu H L-Editor: A P-Editor: Xu ZH Contributor Information Arun Mukesh, Anesthesia and Critical Care, All India Institute of Medical Sciences, Jodhpur 342008, Rājasthān, India. Ankur Sharma, Department of Trauma and Emergency (Anaesthesiology and Critical Care), All India Institute of Medical Sciences, Jodhpur 342008, Rājasthān, India. ankuranaesthesia@gmail.com. Nikhil Kothari, Department of Anaesthesia, All India Institute of Medical Sciences, Jodhpur 342008, Rājasthān, India. References